The initial growth will be due to the increased penetration of fixed-dose combination drugs
(Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.
While HCTZ is part of several fixed-dose combination drugs
, chlorthalidone is available in only three combination products: clonidine (Clorpres), reserpine (Regroton), and atenolol (Tenoretic), Dr.
com/research/cnk25v/hivaids) has announced the addition of the "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs
to Drive Growth" report to their offering.
s new report "Pricing and Reimbursement of Fixed-Dose Combination Drugs
in the United States" to their offering.
com/reports/c92368) has announced the addition of "The Global Market for Fixed-Dose Combination Drugs for Leading Diseases" to their offering.
The Global Market for Fixed-Dose Combination Drugs for Leading Diseases" analyzes products and applications of fixed-dose combination drugs utilized in the treatment of cardiovascular diseases (hypercholesterolemia and hypertension), diabetes, infectious diseases (bacterial infections, Helicobacter pylori, acquired immune deficiency syndrome--AIDS, HIV infection and tuberculosis), psychiatric disorders (depression and Alzheimer's disease) and respiratory diseases (asthma and chronic obstructive pulmonary disease--COPD).
The Disadvantages Of Fixed-Dose Combination Drugs 9
Regulations Relating To Fixed-Dose Combination Drugs 10
Incentives And Barriers To The Development Of Fixed-Dose Combination Drugs 11
The Challenges Of Manufacturing Fixed-Dose Combination Drugs 11
Potential Fixed-Dose Combination Drugs Lead The Market 98
While the cholesterol management market remains dominated by statins and fixed-dose combination drugs
containing statins, the market for drugs to treat hypertension covers a number of classes, such as beta blockers, ACE inhibitors, angiotensin-II receptor antagonists, calcium channel blockers and alpha blockers.